Loading patent…
AssigneesBristol-Myers Squibb Company, Pfizer Inc.
InventorsArvind Rajpal, Madhav Narasimha Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Z. Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
Estimating the term…
Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.
An isolated human monoclonal antibody of antigen-binding portion thereof comprising a heavy chain variable (VH) domain amino acid sequence comprising a CDR1, CDR2, and CDR3 region selected from the group consisting of:
An isolated human antibody or antigen-binding portion thereof comprising a light chain variable (VL) domain amino acid sequence comprising a VL CDR 1 as set forth in SEQ ID NO:16, a VL CDR2 as set forth in SEQ ID NO:17, and a VL CDR3 as set forth in SEQ ID NO:18;
An isolated human monoclonal antibody or antigen-binding portion thereof comprising a heavy chain variable (VH) domain amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:37 and SEQ ID NO:40 or differs from any one of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:37 and SEQ ID NO:40 by having at least one conservative amino acid substitution or differs from any one of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34 SEQ ID NO:37 and SEQ ID NO:40 by having at least one germline amino acid substitution compared to SEQ ID NO:46;
An isolated human monoclonal antibody or antigen-binding portion thereof comprising a light chain variable (VL) domain amino acid sequence selected from the group consisting of SEQ ID NO:15 or differs from SEQ ID NO:15, by having a conservative amino acid substitution, or differs from SEQ ID NO:15, by having a germline amino acid substitution compared to SEQ ID NO:47;
An isolated human monoclonal antibody or antigen-binding portion thereof comprising VL and VH domains at least 90% identical in amino acid sequence to the VL and VH domains, respectively, of antibody 9C8, 9C8 N68T T83S, 9C8 E31G N68T T83S, 9C8 I24V N68T T83S, and 22B5;
An isolated human monoclonal antibody or antigen-binding portion thereof comprising:
An isolated human monoclonal antibody or antigen binding portion thereof comprising a heavy chain having an amino sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:24, SEQ ID NO:28, and SEQ ID NO:32, or differs from any one of SEQ ID NO:3, SEQ ID NO:24, SEQ ID NO:28, and SEQ ID NO:32, by having a conservative amino acid substitution, or differs from any one of SEQ ID NO:3, SEQ ID NO:24, SEQ ID NO:28, and SEQ ID NO:32, by having a germline amino acid substitution compared to their respective germline sequence selected from the group consisting of SEQ ID NO:46;
An isolated human monoclonal antibody or antigen binding portion thereof comprising a light chain having an amino sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:26 and SEQ ID NO:43, or differs from any one of SEQ ID NO:14, SEQ ID NO:26 and SEQ ID NO:43 by having a conservative amino acid substitution, or differs from any one of SEQ ID NO:14, SEQ ID NO:26 and SEQ ID NO:43 by having a germline amino acid substitution compared to the corresponding germline sequence selected from the group consisting of SEQ ID NO:47;
An isolated human monoclonal antibody or antigen binding portion thereof comprising a heavy chain and a tight chain selected from the group consisting of:
Dependencies are inferred from the claim text.